IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy
Immunity · 2026
DOI: 10.1016/j.immuni.2025.10.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, 2026. Verfasst von Sofía Castelli und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cellular Immunotherapies, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philade…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Interleukin-9, Immunotherapy, Adoptive, CD4-Positive T-Lymphocytes. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 78 Literaturangaben. Gefördert von: The Mark Foundation for Cancer Research, National Institutes of Health, Abramson Cancer Center.
Abstract (Originalsprache)
The success of chimeric antigen receptor (CAR) T cell therapies targeting solid tumors is limited by the immunosuppressive tumor microenvironment. We demonstrate that endowing CAR T cells with ectopic interleukin (IL)-9 signaling by co-expressing an IL-9 receptor rewires CAR T cell fate under antigen stress to enhance antitumor efficacy. In preclinical solid tumor models, IL-9-signaling CAR T cells exhibit increased expansion, persistence, and tumor infiltration, resulting in superior tumor control at substantially lower doses than conventional products. Trajectory and RNA velocity analyses of single-cell RNA sequencing data reveal that IL-9 signaling alters CAR T cell differentiation under antigen stress away from dysfunction, favoring a multipotent transition toward CD8+ T cell memory and effector states and promoting a CD4+ cell proliferative state. Interrogation of transcription factor pathways indicates that IL-9-mediated activation of STAT1 and STAT4 may contribute to the superior phenotype of IL-9-signaling CAR T cells, providing a promising therapeutic strategy for targeting solid cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cellular Immunotherapies, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Parker Institute for Cancer Immunotherapy, Unive…
- Comparative Pathology Core, Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Förderung
- The Mark Foundation for Cancer Research
- National Institutes of Health
- Abramson Cancer Center
- Prostate Cancer Foundation
- Deutsche Krebshilfe
- University of Pennsylvania
- Parker Institute for Cancer Immunotherapy
- School of Veterinary Medicine, Louisiana State University
Zitieren
APA
Castelli, S., Wilson, W. V., Uslu, U., Finck, A. V., Rommel, P. C., Assenmacher, C. A., Atoche, S. J., Siurala, M., Aznar, M. A., Young, R. M., & June, C. H. (2026). IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy. Immunity. https://doi.org/10.1016/j.immuni.2025.10.021
Vancouver
Castelli S, Wilson WV, Uslu U, Finck AV, Rommel PC, Assenmacher CA, et al. IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy. Immunity. 2026. doi:10.1016/j.immuni.2025.10.021
BibTeX
@article{Castelli2026,
author = {Castelli, Sofía and Wilson, Wesley V and Uslu, Ugur and Finck, Amanda V and Rommel, Philipp C and Assenmacher, Charles-Antoine and Atoche, Sebastian J and Siurala, Mikko and Aznar, M Angela and Young, Regina M and June, Carl H},
title = {IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy},
journal = {Immunity},
year = {2026},
doi = {10.1016/j.immuni.2025.10.021}
}
EUVIMED